An interventional study of Percutaneous coronary intervention in Acute Coronary Syndrome and Coronary Artery Disease, sponsored by Konstantinos Toutouzas. Withdrawn at 7 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-19.
Sponsored by Konstantinos Toutouzas · Not applicable, Interventional, and Treatment
No funding
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 50 studies in Acute Coronary Syndrome with a site in Belgium — 4 open to participants now, 5 under way, none of them phase 3. Acute Coronary Syndrome · Belgium.
Among the 50 studies in Acute Coronary Syndrome with a site in Belgium, this one is the 43rd largest by enrollment of the 43 interventional ones that give a count, is one of 2 that started in 2024, is one of 16 with no phase, and was the 45th registered.
1,491 studies on the registry are indexed under Acute Coronary Syndrome; 272 are open to participants now.
Browse Acute Coronary Syndrome studies →4 of the 50 studies in Acute Coronary Syndrome with a site in Belgium are open now. Recruiting first, the newest first:
Universitair Ziekenhuis Brussel · Sites in Belgium
Ages 30+
St. Antonius Hospital · Sites in Belgium, Netherlands
Ages 18+
CoreAalst BV · Sites in Belgium, China, France and 5 more countries
Ages 18–85
Aarhus University Hospital Skejby · Sites in Belgium, Denmark, Estonia and 9 more countries
Ages 18+
A study can be open while its sites in Belgium have not opened yet or have stopped. Only those recruiting at a site in Belgium →
Of the 195 Acute Coronary Syndrome studies recruiting now, 144 (74%) set no upper age limit and 19 (10%) stop at 75 or younger; 15 take children under 18; 15 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
50 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 2 started in 2024.
By drug class, each counting the studies that test any of its medicines:
Median enrollment 2,700 across the 43 interventional studies, 1,453 across the 7 observational. Of the 38 that completed or were terminated, 16 (42%) have results posted.
This tab as a report to print or save as PDF → With an account.
28 of 50 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with Konstantinos Toutouzas as lead sponsor.
Konstantinos Toutouzas has 1 study filed under Acute Coronary Syndrome — fewer than ten, so there is no comparison to draw.
3 of the studies in Acute Coronary Syndrome with a site in Belgium that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06845826KU LeuvenPoint-of-Care Troponin Testing in the Emergency Department | 2026-11-30 |
| NCT07192965Universitair Ziekenhuis BrusselECG-less Coronary Computed Tomography Angiography in the Management of Patients Presenting With High-troponin Chest Pain | 2027-09 |
| NCT04436978St. Antonius HospitalWhat is the Optimal Antithrombotic Strategy in Patients With Atrial Fibrillation Undergoing PCI? | 2027-10-01 |
Add all 3 to your calendar (.ics) → With an account.
Among the 50 studies in Acute Coronary Syndrome with a site in Belgium, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a multicentre, prospective, randomized controlled trial that will investigate the role and performance of the 3rd generation resorbable magnesium scaffolds "DREAMS 3G" labeled under the name "Freesolve" vs contemporary biodegradable polymer scaffolds in non ST-segment elevation acute coronary syndromes. Patients fulfilling the eligibility criteria will be enrolled and undergo PCI with either Freesolve or Orsiro platforms for the culprit lesion only. They will be followed-up for 12 months (1, 6 and 12 months). The primary endopoint will be Target Lesion Failure as defined by ARC definitions.
INTRODUCTION AND RATIONALE Scaffolding the coronary vessels while maintaining the physiological and rheological properties was an appealing idea resulting in the development of the bioresorbable scaffolds (BRS). The most thoroughly studied BRS - the poly-L-lactide acid based BRS ABSORB™ - evidenced increased rates of device-related adverse events in the randomized controlled trials (RCT) and was removed from market in 2017. ABSORB was an everolimus eluting BRS, characterized by limited radial force, thicker and wider struts, unfavorable crossing profile and unpredictable resorption.
In an effort to overcome these obstacles, metallic resorbable scaffolds were developed - with the main representative being the resorbable magnesium scaffolds (RMS). The absorbable metal stent (AMS) (BIOTRONIK AG, Bülach, Switzerland). was the first device tested in the PROGRESS-AMS trial showing feasibility but necessity for improvement. DREAMS 1G (BIOTRONIK AG, Bülach, Switzerland) was the first generation of the improved RMS, designed to improve radial force and coated with a paclitaxel-polymer matrix. It was studied in the BIOSOLVE-I and showed improved performance compared to the AMS with no probable or definite scaffold thrombosis, however late-lumen-loss (LLL) was relatively high compared to ABSORB scaffolds and contemporary drug eluting stents (DES).
The second generation was the DREAMS 2G (BIOTRONIK AG, Bülach, Switzerland), gaining CE-Mark in 2016 and marketed as Magmaris™. It is designed with more flexible and stronger scaffold backbone targeting in improved radial force with 150x140μm strut thickness. The drug-polymer coating was substituted by the sirolimus BIOlute™ matrix of the Orsiro™ DES, to decrease more effectively neointimal formation. Also, radiopaque markers were added for enhanced x-ray visibility. The outcomes of Magmaris™ have been investigated in the BIOSOLVE II, III, IV trials. In summary, BIOSOLVE II and III demonstrated no scaffold thrombosis with improved LLL improved to its precursor and BIOSOLVE IV exhibited low event rates in a large single-arm study.
The concept of protecting the vulnerable, eroded or ruptured plaque without a permanent metallic endoprosthesis finds ideal application in the acute coronary syndromes. Culprit lesions present as a ruptured plaque, plaque erosion or less frequently as a calcific nodule complicated by thrombotic burden and implantation of a BRS may adequately revascularize the vessel, protect the lesion and be resorbed after vessel healing restoring its elastic and hydraulic properties. However, the high thrombotic status of an acute coronary syndrome (ACS) was preventing BRS of being utilized in such situations. The TROFI-II RCT compared the ABSORB scaffold with DES in ST-segment elevation myocardial infarction (STEMI) and 6-month results were comparable. The Magmaris™ was tested in STEMI patients in the MAGSTEMI RCT and showed significantly higher vasodilatory response at 1-year compared to Orsiro™. Furthermore, Magmaris™ did not raise thrombotic concerns, but resulted in higher target lesion revascularization (TLR) rates although not powered for those endpoints. The BESTMAG trial was a small propensity-matching study providing hypothesis generating outcomes of numerically higher TLR rates with Magmaris™ compared to contemporary biodegradable polymer (BP) or durable polymer (DP)-DES in STEMI presentations. The BIOSOLVE IV registry (n=206) underwent PCI because of non ST-segment elevation (NSTE) myocardial infarction and target vessel failure (TVL) was calculated at 6.1% in 12 months. One death (0.5%) and 2 thrombotic complications were reported (1%). Smaller registries that included NSTE/ACS patients treated with Magmaris™ RMS demonstrated zero deaths and scaffold thrombosis, albeit these are hypothesis generating results limited by the small sample.
The BIOMAG-I first-in-human study investigated the third generation Freesolve™ RMS. The main characteristics are a refined magnesium alloy to enhance scaffolding properties, increased scaffold marker x-ray visibility, larger size range, thinner strut thickness and predictable full resorption in about 12 months. The 1-year results of the BIOMAG-I showed lower LLL (38% lower) than the BIOSOLVE II, low target lesion failure (TLF) rates and no death, target vessel myocardial infarction (MI) or scaffold thrombosis. Of note no struts ware visible in the 1-year optical coherence tomography (OCT). 20.7% of the patients presented with NSTE myocardial infarction lesions and were treated accordingly.
The current guidelines of the European Society of Cardiology recommend use of the BRS only in the context of clinical trials. However, more data and devices are available to hypothesize that RMS may provide a potentially reliable and safe alternative to DES. This trial will further investigate and evaluate the safety and efficacy of the 3rd generation Freesolve™ RMS in NSTE/ACS patients.
STUDY PROCEDURES Screening Patients who will undergo coronary angiography because of NSTE/ACS will be screened for eligibility criteria after signing the informed consent. Demographics, medical history, clinical examination, 12-lead electrocardiogram and per local practice blood laboratory tests will be performed. For women of child-bearing potential, a blood pregnancy test must be performed.
Randomization - enrolment Patients screened and fulfilling eligibility criteria will be enrolled after signing the informed consent form as per RESORB-ACS enrolment and follow-up algorithms (Figure 1). They will be randomly assigned in 1:1 ratio to receive either the Freesolve™ RMS or the BP DES Orsiro® for the PCI of the index NSTE/ACS culprit vessel. The Intention to Treat (ITT) and the Per Protocol (PP) population will only be based on enrolled subjects.
Index PCI All patients enrolled will undergo PCI of the culprit lesion according on the local practice. The instruction for use (IFU) will be followed for every scaffold implantation. In the BP DES arm, the standard DES PCI procedure per local practice will be followed.
Post-procedural care Patients enrolled that have undergone PCI will receive standard NSTE/ACS and post-PCI care in each centre. Double antiplatelet treatment is recommended for at least 12 months.
Follow-up Follow-up will be performed at 1, 6, 12 months and annually up to 36 months follow-up. (visit window ± 10 days). In case that there is no adverse event or complaint from the patient that requires physical examination, the follow-up visits may be conducted through telephone or video call with the investigators.
Study exit Screen failure, withdrawal of the informed consent, lost to follow-up and PCI without scaffold implantation will result in early termination.
Study completion Subject who completes all protocol-required study procedures and follow-ups will complete the trial.
Examinations Clinical examination including angina status or myocardial ischemia, 12-lead electrocardiogram and per local practice blood laboratory tests including will be performed at screening, and during hospitalization post-PCI. Follow-ups will be clinically driven with thorough history primarily focused on any possible myocardial ischemia symptoms. Based on the investigators' - treating physicians' clinical suspicion more examination may be performed to investigate the existence of adverse events/endpoints.
PROCEDURAL DETAILS The device The Freesolve™ scaffold is a Magnesium alloy fully resorbable scaffold developed by BIOTRONIC and represents the 3rd generation of RMS (DREAMS 3G). It is indicated for improving the luminal diameter for treatment of de novo coronary artery lesions by PCI.
Freesolve™ is a scaffold system consisting of a balloon-expandable bioabsorbable scaffold pre-mounted on the balloon of a rapid-exchange PTCA catheter. The scaffold backbone is made from bioabsorbable Magnesium and contains two permanent x-ray markers made from Tantalum on the distal and on the proximal scaffold end, respectively. The surface of the scaffold backbone is completely coated with bioresorbable PLLA (Poly-L-Lactidic Acid) which incorporates Sirolimus. Sirolimus load is 1.4 ± 0.3 μg per mm2 scaffold surface. The DREAMS 3G scaffold system is packaged in a dispenser. The dispenser is placed in an aluminium Tyvek pouch. The device is sterilized using ethylene oxide sterilization. In vivo investigations using a porcine model show that DREAMS 3G provides vessel support for about 3-6 months and releases around 70% Sirolimus from the PLLA carrier during a period of 3 months after implantation. The drug coating is based on the BIOlute® platform.
Training The operators and the operating teams that are going to participate in this protocol and implant the RMS have to be trained on the consensus paper by Fajadet et al. and follow the "4P" principles.
Device implantation - procedure The RMS Freesolve™ is available in 2.5mm, 3mm, 3.5mm and 4mm diameter and in 13mm, 22mm length for all diameters and 26mm/30mm length for the 3mm, 3.5 mm and 4mm diameters. It can be expander after post-dilatation up to 0.6mm in diameter. Nominal pressure for implantation inflation is 10atm and rated burst pressure 16atm. It is delivered through 6Fr guiding catheter and over angioplasty 0.014'' wires.
Following intracoronary injection of nitroglycerin or isosorbide dinitrate, a baseline angiography of the target vessel must be performed in at least 2 orthogonal views, presenting the target lesion free of foreshortening or vessel overlap. In addition to the clinical routine, OCT and intravascular ultrasound (IVUS) documentation may be done pre-PCI per operator's discretion. By intravascular imaging, detailed examination of the lesion as well as accurate length and reference diameter can be performed.
Lesion access is up to the discretion of the investigator. Pre-dilatation of the target lesion is mandatory. The use of intravascular lithotripsy, drug coated balloons or rotational/orbital atherectomy device is not allowed. Pre-dilatation with a non-compliant balloon with a 1:1 balloon-to-artery ratio is mandatory. The balloon should expand fully with no "waist" at full expansion. Non-compliant balloons are more predictable and are recommended. The residual stenosis before the RMS implantation is required to be ≤ 20%, confirmed by any method and TIMI flow should be III.
The scaffold length should cover the target lesion from normal reference vessel diameter proximally to normal vessel distally to assure full coverage of the lesion. The diameter of the RMS should be chosen as following: 2.5mm for 2.5-2.7mm distal reference diameter (DRD), 3.0mm for 2.7-3.2mm DRD, 3.5mm for 3.2-3.7mm DRD, 4.0mm for 3.7-4.2 DRD. The length should be chosen based on the lesion length by angiography or IVUS, OCT. Only one clinical investigation scaffold should be used per lesion. After scaffold implantation an angiography must be performed following intracoronary injection of nitroglycerine or isosorbide dinitrate. Post-dilatation with a non-compliant balloon of up to 0.5 mm larger than the nominal scaffold size and at high pressure (>16 atm) is mandatory. The use of cutting/scoring or drug coated balloons after RMS implantation is not allowed. After post-dilatation, all subjects will undergo the routine angiography and possibly OCT/IVUS. Intravascular imaging may evaluate expansion, apposition and any possible edge or in-scaffold complication.
Culprit lesion In NSTE/ACS identification of the culprit lesion might be challenging. Investigational data with cardiac magnetic resonance imaging identification has showed that in up to 27% of the NSTE/ACS patients' revascularization has been performed in non-culprit lesions. Moreover, electrocardiographic identification is neither sensitive nor specific and recent data demonstrated that in 14% of the studied patients, conventional angiography failed to identify the culprit lesion. In those ambiguous cases, intravascular imaging with IVUS or OCT plays a critical role in the characterization and identification of the culprit lesion. In the RESORB-ACS trial, operators will decide about the possible culprit lesion and that decision may be assisted and guided by intravascular imaging in case it is needed.
Multivessel disease Multivessel disease is not an exclusion criterion except for the cases that CABG is programmed. Enrolled subjects may undergo PCI with RMS only for the culprit lesion during the index procedure. However, in cases that multivessel disease amenable to PCI is present, operators can proceed to full revascularization with conservative DES or Freesolve™ RMS.
Treatment failure and bailout situation For dissections occurring during, or immediately after implantation of RMS, a second RMS may be used, not overlapping with initial one but implanted end-to- end. If another stent needs to be implanted in the immediate vicinity of an already implanted RMS only a Freesolve™ coronary scaffold system should be used. Contact of the Freesolve™ with an uncoated or polymer coated stent up to 120 days may result in accelerated resorption of the DREAMS 3G and undesired local and downstream effects. After 120 days any other stent type may be used. In case of bailout, If a Freesolve™ is not possible to be used, an Orsiro® DES with its proBIO® passive coating and BIOlute® active coating is recommended to be implanted directly adjacent or minimally overlapping based on the consensus recommendations.
Medication Every patient included in this trial must be able to receive 12-month DAPT with aspirin and clopidogrel or ticagrelor or prasugrel. The timing and necessity (in case the patient was already under antiplatelet treatment) will be at the discretion of the treating physician. At all cases DAPT must be present at the time of the implantation based on the ESC guidelines doses for the management of ACS. The use of anticoagulation during PCI (heparin or enoxaparine) at therapeutic dose for PCI will be chosen by the operators. IIb/IIIa glycoprotein inhibitors as well as vasomotor medications will be left at operators' discretion. After the PCI, all patients must receive at least 12-month DAPT. After 12 months, DAPT may be changed to single treatment with aspirin/clopidogrel/ticagrelor/prasugrel or prolonged based on the balance of ischemic/hemorrhagic risk of the patient. Regarding patients receiving oral anticoagulation (eg atrial fibrillation, prosthetic valve, thrombophilia) we recommend that DAPT should be maintained until 1-month follow-up. Afterwards DAPT can be downsized to either aspirin or clopidogrel alone combined with oral anticoagulant for the remaining time period up to 12 months. After 12 months, monotherapy with oral anticoagulant may be prescribed and continued indefinitely.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
3rd generation resorbable magnesium scaffolds
Device: Percutaneous coronary intervention
Biodegradable polymer drug eluting stents
Device: Percutaneous coronary intervention
Percutaneous coronary intervention with scaffold implantation in patients with NSTE/ACS
Target lesion failure rates
cardiovascular death, myocardial infarction (target vessel) and target lesion renascularization (clinically driven)
Time frame: 12 months
Target lesion revascularization rates
Clinically driven target lesion revascularization
Time frame: 1, 6, 12 months and annually up to 36 months
Cardiac death rates
Cardiac death
Time frame: 1, 6, 12 months and annually up to 36 months
All-cause mortality rates
All-cause mortality
Time frame: 1, 6, 12 months and annually up to 36 months
Target vessel myocardial infarction rates
Target vessel myocardial infarction
Time frame: 1, 6, 12 months and annually up to 36 months
Definite and probable scaffold thrombosis rates
Definite and probable scaffold thrombosis
Time frame: 1, 6, 12 months and annually up to 36 months
Device success rates
Device success defined as final residual diameter stenosis of \<30% by angiographic visual assessment using the assigned device only and successful delivery of the RMS/DES to the target lesion, appropriate RMS/DES deployment, successful removal of the delivery system.
Time frame: Peri-procedurally
Plan to share: No
Start is estimated for Oct 2024; primary completion for Dec 2027, 38 months later.
How these figures are worked out, and which studies are left out of them.
No funding
No funding
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is withdrawn, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.